Skip to main
IVVD

Invivyd Inc (IVVD) Stock Forecast & Price Target

Invivyd Inc (IVVD) Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 75%
Buy 25%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Invivyd is a promising biopharmaceutical company with a strong focus on monoclonal antibody therapies for viral infections, such as COVID-19 and RSV. Their lead product, PEMGARDA, has already received emergency use authorization and is expected to receive full approval in the near future, providing a strong revenue potential. The company's new antibody candidate, VYD2311, has shown promising results in clinical trials and has the potential to secure a significant portion of the market by 2030. However, the company may face competition and risks in the constantly evolving and competitive vaccine development industry.

Bears say

Invivyd is a biopharmaceutical company focused on monoclonal antibody therapies for viral diseases, with their lead product receiving emergency use authorization for COVID-19. However, the company's focus on infectious diseases and emerging variants leaves them vulnerable to changing market demands and potential competition. Additionally, with a relatively small pipeline of vaccine candidates, Invivyd's financial success heavily relies on the success of Pemgarada and its ability to secure partnerships or licensing agreements for future products. Without a diverse portfolio and limited financial resources, Invivyd may struggle to stay competitive in the highly dynamic and competitive biopharmaceutical industry.

Invivyd Inc (IVVD) has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 75% of analysts recommend a Strong Buy, 25% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Invivyd Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Invivyd Inc (IVVD) Forecast

Analysts have given Invivyd Inc (IVVD) a Strong Buy based on their latest research and market trends.

According to 4 analysts, Invivyd Inc (IVVD) has a Strong Buy consensus rating as of May 1, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Invivyd Inc (IVVD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.